Emendo Biotherapeutics Raises $61 Million to Advance Next Generation Genome Editing Therapeutics
15.1.2020 14:00:00 EET | Business Wire | Press release
Emendo Biotherapeutics, a leader in next-generation gene editing using synthetic biology to address untreatable diseases, today announced a Series B investment totaling $61 million led by AnGes, Inc., a Japan-based biopharma, reflecting its strategic interest in partnering with Emendo on the development of specific indications.
“This financing provides a strong foundation from which we can accelerate our proprietary OMNI gene editing platform towards a broad clinical pipeline for addressing devastating untreatable diseases,” said Dr. David Baram, President & CEO, Emendo Biotherapeutics. “We are grateful for such strong support from so many high-quality investors and strategic partners including AnGes, OrbiMed Advisors, OrbiMed Israel Partners and Takeda Ventures who share our vision to translate this powerful science into transformative medicines.”
Emendo Biotherapeutics is pioneering OMNI, a next-generation allele-specific gene editing platform that uses synthetic biology to expand what is possible in genome-editing. In 2019, Emendo granted an option to Takeda to use the OMNI nuclease gene editing program for two research and development targets. Emendo received an undisclosed investment from Takeda Ventures that was converted in the Series B.
Emendo’s OMNI technology enables precision gene editing while maintaining high efficiencies, uniquely addressing dominant indications such as Severe Congenital Neutropenia (SCN), caused by mutations in the neutrophil elastase gene ELANE. Dominant indications represent the vast majority of genetic diseases which until now have been untreatable.
About AnGes
AnGes is a Tokyo and Osaka, Japan-based biopharmaceutical company focused on the development and commercialization of gene-based medicines including gene therapy and oligonucleotide molecules. AnGes’ lead product HGF plasmid, which received conditional approval in Japan in 2019, is a DNA plasmid which encodes the human Hepatocyte Growth Factor (HGF) gene, an angiogenic (new blood vessel growth) factor for critical limb ischemia (CLI). The company is also developing NF-kB Decoy oligonucleotide for the treatment of inflammatory diseases. For more information please visit www.anges.co.jp.
About Emendo
Emendo Biotherapeutics is transforming the landscape of genome-editing based medicine through its use of novel CRISPR nucleases, advanced cutting-edge protein engineering platforms, diverse pipeline of clinical programs and extensive intellectual property portfolio. For more information please visit us at www.emendobio.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200115005379/en/
Contact information
Julie Amar
info@emendobio.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Sofinnova Partners Promotes Javier Nunez-Vicandi to Partner, Strengthening Its Digital Medicine Strategy2.11.2026 09:00:00 EET | Press release
Sofinnova Partners ("Sofinnova"), a leading European venture capital firm in life sciences, based in Paris, London, and Milan, today announced the promotion of Javier Nunez-Vicandi to Partner. He joins Edward Kliphuis and Simon Turner in the firm’s Digital Medicine strategy, which invests in startups working at the intersection of biology, data, and AI. Since joining Sofinnova in 2022, Nunez-Vicandi has played a key role in the development of the firm's Digital Medicine strategy and broader AI efforts. He helped shape key AI investment theses within the Digital Medicine Strategy and is an observer on the boards of Latent Labs, Bioptimus, Cure51, Deepc, and Kiro. Javier has also recently led an investment that remains in stealth. Within Sofinnova's broader AI efforts, Javier co-led the project that created Sofia, Sofinnova's proprietary AI platform, which supports investments and scientific analysis. As part of this effort, Javier helped lead the firm's collaborations with AWS and NVIDI
SES to Supply Finnair with Ground-like Connectivity Experience in the Skies2.11.2026 09:00:00 EET | Press release
SES today announced a new agreement with Finnair, Finland's flagship airline, to equip 18 E195-E2s with multi-orbit in-flight connectivity, enabling Finnair’s customers to enjoy fast, reliable internet access throughout their journey. Under the agreement, the Embraer E2 aircraft, which will be line-fitted at Embraer, will be equipped with SES’s electronically steered array antenna (ESA) offering reliable connectivity to the SES multi-orbit network, combining SES’s geostationary (GEO) satellite services with low-earth orbit (LEO) capacity from its partner Eutelsat. The first connected aircraft is expected to enter service in 2027. “Inflight Wi-Fi is a core part of the travel experience,” said Blane Boynton, Senior Vice President Aviation at SES. “SES’s multi-orbit network delivers the reliability, performance and flexibility airlines need today while providing a clear path for future growth. This agreement is another testament to the growing confidence leading airlines are placing in ou
Speech Processing Solutions Launches Philips SpeechLive Legal Direct and Philips SpeechLive Professional Direct with Real-Time Speech Recognition Directly at Cursor2.11.2026 09:00:00 EET | Press release
Speech Processing Solutions (SPS), the global leader in professional dictation and transcription solutions sold under the Philips brand, today announced the launch of Philips SpeechLive Legal Direct and Philips SpeechLive Professional Direct. The two solutions allow legal and other professionals to dictate into supported desktop applications, with recognized text appearing as they speak. They are designed both for organizations adopting professional speech recognition for the first time and for customers moving from established or end-of-life speech recognition solutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261029365830/en/ Philips SpeechLive Legal Direct – legal speech recognition, directly at cursor With support of 29 voice commands across 19 languages, these new solutions combine familiar dictation practices with commands covering navigation, selection, editing, formatting, lists and help functions. Professiona
Thales Selected to Deliver Next-Generation Mine-Hunting Capability for the U.S. Navy2.11.2026 08:00:00 EET | Press release
Thales’ subsidiary Advanced Acoustic Concepts (AAC), a U.S.-based provider of undersea warfare solutions, was awarded a $53.9 million U.S. Navy contract to produce and deliver two integrated Remote Mine Hunting (RMH) modules and accompanying engineering support. The award includes options for additional modules that could increase the total cumulative contract value to approximately $196.2 million. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261101304707/en/ Sonar ©Thales The RMH solution supports the Navy's Mine Countermeasures (MCM) mission through the proven “Find, Fix and Finish” approach to defeating mine threats. The capability enables sailors to remotely detect, locate and classify undersea mines, while operating from safer stand-off distances, enhancing mission effectiveness and reducing risk in contested maritime environments. “The ability to counter undersea mine threats remains fundamental to maritime security
Uptime Institute and Indonesia Ministry of Communication and Digital Affairs (KOMDIGI) Sign Letter of Intent (LOI) to Support Data Center Policy, Governance, and Industry Development2.11.2026 07:04:00 EET | Press release
Uptime Institute, the Global Digital Infrastructure Authority, and the Ministry of Communication and Digital Affairs (Komdigi) today announced the signing of a Letter of Intent (LOI) to explore collaboration aimed at strengthening Indonesia's data center ecosystem through policy development, governance frameworks, operational excellence, security, sustainability, and workforce capability development. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261101628182/en/ Uptime Institute and KOMDIGI sign LOI. The Letter of Intent reflects a shared interest in exploring international best practices that may support the development of reliable, secure, efficient, and sustainable digital infrastructure aligned with Indonesia's national priorities and regulatory framework. The LOI was signed by Mustapha Louni, Chief Business Officer, Uptime Institute, and Wayan Toni Supriyanto, Director General of Digital Infrastructure, Indonesia's Min
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom